- Home
- SOPH vs RIGL Comparison
SOPH vs RIGL Comparison
Compare SOPH & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOPH | RIGL |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.4M | 537.6M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | SOPH | RIGL |
|---|---|---|
| Price | $4.51 | $44.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $7.00 | ★ $43.20 |
| AVG Volume (30 Days) | 76.0K | ★ 498.4K |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2698.26 |
| EPS | N/A | ★ 6.20 |
| Revenue | $73,297,000.00 | ★ $282,076,000.00 |
| Revenue This Year | $18.32 | $65.53 |
| Revenue Next Year | $15.61 | $0.22 |
| P/E Ratio | ★ N/A | $7.20 |
| Revenue Growth | 13.66 | ★ 79.13 |
| 52 Week Low | $2.58 | $14.63 |
| 52 Week High | $5.30 | $52.24 |
Technical Indicators
Market Signals| Indicator | SOPH | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 47.87 | 55.88 |
| Support Level | $4.60 | $40.52 |
| Resistance Level | $4.84 | $43.58 |
| Average True Range (ATR) | 0.23 | 2.42 |
| MACD | -0.03 | -0.33 |
| Stochastic Oscillator | 17.51 | 48.65 |
Price Performance
Historical ComparisonAbout SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.